Search

Your search keyword '"Lee, Jung-Yun"' showing total 929 results
Start Over Author "Lee, Jung-Yun"
929 results on '"Lee, Jung-Yun"'

10. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Author

Lorusso, Domenica, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Sukhin, Vladyslav, Cloven, Noelle, Pereira de Santana Gomes, Andrea J, Contreras Mejía, Fernando, Reiss, Ari, Ayhan, Ali, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Lazzari, Roberta, Chang, Chih-Long, Lampé, Rudolf, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Polterauer, Stephan, Usami, Tomoka, Li, Kan, Yamada, Karin, Toker, Sarper, Keefe, Stephen M, Pignata, Sandro, and Duska, Linda R

Published
2024
Full Text
View/download PDF

12. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)

Author

Lee, Yong Jae, Seol, Aeran, Lee, Maria, Kim, Jae-Weon, Kim, Hee Seung, Kim, Kidong, Suh, Dong Hoon, Kim, Sunghoon, Kim, Sang Wun, and Lee, Jung-Yun

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Genetics, Cancer, Ovarian Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Carcinoma, Ovarian Epithelial, Doxorubicin, Female, Humans, Neoplasm Recurrence, Local, Ovarian Neoplasms, Platinum, Polyethylene Glycols, BRCA, antitumor activity, pegylated liposomal doxorubicin, platinum-resistant recurrent ovarian cancer, Oncology & Carcinogenesis, Clinical sciences, Dentistry, Oncology and carcinogenesis
Abstract

Background/aimThe majority of targeted therapies are focused on BRCA mutations, homologous recombination repair deficiency, and BRCA wild-type platinum-sensitive recurrent ovarian cancer. There is a growing need for platinum-resistant patients without BRCA mutations. Herein, we conducted a phase II multicenter study evaluated the efficacy and safety of bortezomib plus pegylated liposomal doxorubicin (PLD) in patients with BRCA wild-type platinum-resistant recurrent ovarian cancer (NCT03509246).Patients and methodsOvarian cancer patients with wild-type BRCA who experienced platinum-resistant recurrence after three or less prior treatment cycles from three Institutions were included. All patients received bortezomib, 1.3 mg/m2 subcutaneously (days 1, 4, 8, and 11), and PLD, 40 mg/m2 intravenously (day 4), every 4 weeks. The primary endpoint was best objective response rate (ORR), and secondary endpoints included disease control rate, progression-free survival (PFS), overall survival, and safety. Targeted sequencing was performed to evaluate biomarkers and their potential association with response to treatment.ResultsThe trial was terminated after 23 patients were recruited because of slow accrual. The median follow-up was 29.5 months. The overall ORR was 8.7% (2/23); partial response was observed in two patients. The median duration of response was 10.5 months, and median PFS was 2.9 months. Treatment-related adverse events (TRAEs) of grade 3/4 were reported in 43.5% of patients. One patient who exhibited TRAEs discontinued treatment. However, grade 4/5 TRAEs were not observed. Mutations in TP53 and CDK12 were detected in 67% (14/21) and 24% (12/21) of patients, respectively. Two patients with partial response harbored mutations in genes related to homologous recombination repair deficiency, including BRCA2, ATM, and CDK12.ConclusionThe combination of bortezomib and PLD was well tolerated; however, antitumor activity was not sufficient to warrant further investigation in ovarian cancer.

Published
2022

14. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Author

Monk, Bradley J, Toita, Takafumi, Wu, Xiaohua, Vázquez Limón, Juan C, Tarnawski, Rafal, Mandai, Masaki, Shapira-Frommer, Ronnie, Mahantshetty, Umesh, del Pilar Estevez-Diz, Maria, Zhou, Qi, Limaye, Sewanti, Godinez, Francisco J Ramirez, Oppermann Kussler, Christina, Varga, Szilvia, Valdiviezo, Natalia, Aoki, Daisuke, Leiva, Manuel, Lee, Jung-Yun, Sulay, Raymond, Kreynina, Yulia, Cheng, Wen-Fang, Rey, Felipe, Rong, Yi, Ke, Guihao, Wildsmith, Sophie, Lloyd, Andrew, Dry, Hannah, Tablante Nunes, Ana, and Mayadev, Jyoti

Published
2023
Full Text
View/download PDF

15. Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer

Author

Ahn, Byungsoo, Moon, Damin, Kim, Hyun-Soo, Lee, Chung, Cho, Nam Hoon, Choi, Heung-Kook, Kim, Dongmin, Lee, Jung-Yun, Nam, Eun Ji, Won, Dongju, An, Hee Jung, Kwon, Sun Young, Shin, Su-Jin, Jung, Hye Ra, Kwon, Dohee, Park, Heejung, Kim, Milim, Cha, Yoon Jin, Park, Hyunjin, Lee, Yangkyu, Noh, Songmi, Lee, Yong-Moon, Choi, Sung-Eun, Kim, Ji Min, Sung, Sun Hee, and Park, Eunhyang

Published
2024
Full Text
View/download PDF

18. An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).

Author

Choi, Chel Hun, primary, Kim, Byoung-Gie, additional, Lee, Jeong-Won, additional, Kim, Tae-Joong, additional, Lee, Yoo-Young, additional, Cho, Duck, additional, Park, Byoung-Kwan Hun, additional, Song, Sang Yong, additional, Kim, Dae-Yeon, additional, Kim, Kidong, additional, Kim, Hee Seung, additional, Lee, Jung-Yun, additional, Lim, Myong Cheol, additional, Jeon, Insu, additional, Song, By-yeong, additional, Shin, Kwang-Soo, additional, Kim, Wuhyun, additional, and Kang, Chang-Yuil, additional

Published
2024
Full Text
View/download PDF

19. Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.

Author

Manso, Luis, primary, Vergote, Ignace, additional, Fujiwara, Keiichi, additional, Angelergues, Antoine, additional, Zikan, Michal, additional, Jordan, Scott, additional, Lee, Jung-Yun, additional, Barraclough, Lisa, additional, Maluf, Fernando Cotait, additional, Lorusso, Domenica, additional, Yonemori, Kan, additional, Gennigens, Christine, additional, Gonzalez Martin, Antonio, additional, Heitz, Florian, additional, Westermann, Anneke M., additional, Covens, Allan, additional, Whalley, Elizabeth, additional, Chen, Yiyi, additional, Soumaoro, Ibrahima, additional, and Randall, Leslie M., additional

Published
2024
Full Text
View/download PDF

20. Comparison of single-port laparoscopy and laparotomy in early ovarian cancer surgical staging

Author

Cho, Kyu Hee, Lee, Yeon Ju, Eoh, Kyung Jin, Lee, Yong Jae, Lee, Jung-Yun, Nam, Eun Ji, Kim, Sunghoon, Kim, Young Tae, and Kim, Sang Wun

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Patient Safety, Cancer, Rare Diseases, Ovarian Cancer, Clinical Research, Cancer staging, Laparoscopic surgery, Laparotomy, Minimal invasive surgery, Ovary, Reproductive medicine
Abstract

Objectives The aims of this study were to assess the feasibility of single-port laparoscopic surgical staging (SPLS) in early ovarian cancer and to compare the surgical outcomes of SPLS with those of staging laparotomy.MethodsBetween January 2014 and December 2018, 40 patients underwent SPLS and 41 patients underwent staging laparotomy at Yonsei Cancer Center. The patients were diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I ovarian cancer. Variables such as patient age, body mass index (BMI), tumor size, FIGO stage, and perioperative surgical outcomes and survival outcomes of SPLS and laparotomy were compared.ResultsThe total operation time was similar between the 2 groups (SPLS: 201.4 vs. laparotomy: 203.0 minutes, P=0.806). The median tumor diameters in the SPLS and laparotomy groups were 11.0 (2.5-28 cm) and 15.4 (6-40 cm), respectively (P=0.001). The SPLS group had lower tumor spillage rate (5.0% vs. 19.5%, P=0.047), less intraoperative blood loss (102.0 vs. 371.5 mL, P

Published
2021

22. 4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

Author

Kim, Hyung‐Don, Park, Seongyeol, Jeong, Seongju, Lee, Yong Joon, Lee, Hoyoung, Kim, Chang Gon, Kim, Kyung Hwan, Hong, Seung‐Mo, Lee, Jung‐Yun, Kim, Sunghoon, Kim, Hong Kwan, Min, Byung Soh, Chang, Jong Hee, Ju, Young Seok, Shin, Eui‐Cheol, Song, Gi‐Won, Hwang, Shin, and Park, Su‐Hyung

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Rare Diseases, Digestive Diseases, Cancer, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Aged, CD8-Positive T-Lymphocytes, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating, Male, Middle Aged, Programmed Cell Death 1 Receptor, Tumor Necrosis Factor Receptor Superfamily, Member 9, Medical Biochemistry and Metabolomics, Clinical Sciences, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsTargeting costimulatory receptors with agonistic antibodies is a promising cancer immunotherapy option. We aimed to investigate costimulatory receptor expression, particularly 4-1BB (CD137 or tumor necrosis factor receptor superfamily member 9), on tumor-infiltrating CD8+ T cells (CD8+ tumor-infiltrating lymphocytes [TILs]) and its association with distinct T-cell activation features among exhausted CD8+ TILs in hepatocellular carcinoma (HCC).Approach and resultsTumor tissues, adjacent nontumor tissues, and peripheral blood were collected from HCC patients undergoing surgical resection (n = 79). Lymphocytes were isolated and used for multicolor flow cytometry, RNA-sequencing, and in vitro functional restoration assays. Among the examined costimulatory receptors, 4-1BB was most prominently expressed on CD8+ TILs. 4-1BB expression was almost exclusively detected on CD8+ T cells in the tumor-especially on programmed death 1 (PD-1)high cells and not PD-1int and PD-1neg cells. Compared to PD-1int and 4-1BBneg PD-1high CD8+ TILs, 4-1BBpos PD-1high CD8+ TILs exhibited higher levels of tumor reactivity and T-cell activation markers and significant enrichment for T-cell activation gene signatures. Per-patient analysis revealed positive correlations between percentages of 4-1BBpos cells among CD8+ TILs and levels of parameters of tumor reactivity and T-cell activation. Among highly exhausted PD-1high CD8+ TILs, 4-1BBpos cells harbored higher proportions of cells with proliferative and reinvigoration potential. Our 4-1BB-related gene signature predicted survival outcomes of HCC patients in the The Cancer Genome Atlas cohort. 4-1BB agonistic antibodies enhanced the function of CD8+ TILs and further enhanced the anti-PD-1-mediated reinvigoration of CD8+ TILs, especially in cases showing high levels of T-cell activation.Conclusion4-1BB expression on CD8+ TILs represents a distinct activation state among highly exhausted CD8+ T cells in HCC. 4-1BB costimulation with agonistic antibodies may be a promising strategy for treating HCCs exhibiting prominent T-cell activation.

Published
2020

23. Anti-4-1BB×PD-L1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD-1 Blockade

Author

Jeon, Seung Hyuck, primary, You, Gihoon, additional, Park, Junsik, additional, Chung, Youseung, additional, Park, Kyungjin, additional, Kim, Hyunjoo, additional, Jeon, Jaehyoung, additional, Kim, Youngkwang, additional, Son, Woo-Chan, additional, Jeong, Da Som, additional, Shin, Eui-Cheol, additional, Lee, Jung-Yun, additional, Han, Dai Hoon, additional, Jung, Jaeho, additional, and Park, Su-Hyung, additional

Published
2024
Full Text
View/download PDF

25. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy

Author

Jeon, Seung Hyuck, primary, Kang, Minyong, primary, Jeon, Minwoo, primary, Chung, Youseung, primary, Kim, A Reum, primary, Lee, Yong Joon, primary, Kim, Eui-Soon, primary, Nam, Heejin, primary, Park, Junsik, primary, Lee, Jung-Yun, primary, Shin, Eui-Cheol, primary, Seo, Seong Il, primary, and Park, Su-Hyung, primary

Published
2024
Full Text
View/download PDF

26. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy

Author

Jeon, Seung Hyuck, primary, Kang, Minyong, primary, Jeon, Minwoo, primary, Chung, Youseung, primary, Kim, A Reum, primary, Lee, Yong Joon, primary, Kim, Eui-Soon, primary, Nam, Heejin, primary, Park, Junsik, primary, Lee, Jung-Yun, primary, Shin, Eui-Cheol, primary, Seo, Seong Il, primary, and Park, Su-Hyung, primary

Published
2024
Full Text
View/download PDF

27. Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study

Author

Choi, Chel Hun, primary, Lee, Jeong-Won, additional, Bae, Duk-Soo, additional, Kang, Eun-Suk, additional, Cho, Duck, additional, Kim, Yong-Man, additional, Kim, Kidong, additional, Kim, Jae-Weon, additional, Kim, Hee Seung, additional, Kim, Young-Tae, additional, Lee, Jung-Yun, additional, Lim, Myong Cheol, additional, Oh, Taegwon, additional, Song, Boyeong, additional, Jeon, Insu, additional, Park, Myunghwan, additional, Kim, Wu Hyun, additional, Kang, Chang-Yuil, additional, and Kim, Byoung-Gie, additional

Published
2024
Full Text
View/download PDF

30. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Marth, Christian, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Vergote, Ignace, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Candido dos Reis, Francisco Jose, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Paoletti, Xavier, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Bruchim, Ilan, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Enomoto, Takayuki, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Oza, Amit M, Heinzelmann, Viola, Gourley, Charlie, Roxburgh, Patricia, Herrington, C Simon, Glasspool, Ros, Zang, Rongyu, Zhu, Jianqing, Gonzalez-Martin, Antonio, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Stuart, Gavin C E, and Bookman, Michael A

Published
2022
Full Text
View/download PDF

31. Table S1-S5, Figure S1-S3 from Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer

Author

Heo, Jinho, primary, Kim, Yoo-Na, primary, Shin, Saeam, primary, Lee, Kyunglim, primary, Lee, Ji-Hyun, primary, Lee, Yong Jae, primary, Choi, Zisun, primary, Park, Jihyang, primary, Min, Seungki, primary, Kim, Sang Wun, primary, Choi, Jong Rak, primary, Kim, Sunghoon, primary, Lee, Seung-Tae, primary, and Lee, Jung-Yun, primary

Published
2024
Full Text
View/download PDF

32. Data from Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer

Author

Heo, Jinho, primary, Kim, Yoo-Na, primary, Shin, Saeam, primary, Lee, Kyunglim, primary, Lee, Ji-Hyun, primary, Lee, Yong Jae, primary, Choi, Zisun, primary, Park, Jihyang, primary, Min, Seungki, primary, Kim, Sang Wun, primary, Choi, Jong Rak, primary, Kim, Sunghoon, primary, Lee, Seung-Tae, primary, and Lee, Jung-Yun, primary

Published
2024
Full Text
View/download PDF

36. DOMENICA study (GINECO-EN105b/ENGOT-en13): randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting (APGOT-EN1)

Author

Choi, Chel Hun, primary, Ray-Coquard, Isabelle, additional, Rubio, Maria Jesus, additional, Paoletti, Xavier, additional, Hudson, Emma, additional, Lorusso, Domenica, additional, Hasler-Strub, Ursula, additional, Vardar, Mehmet Ali, additional, Lheureux, Stéphanie, additional, Gorp, Toon Van, additional, Tan, David Shao Peng, additional, Trillsch, Fabian, additional, Eberst, Lauriane, additional, Lescure, Céline, additional, Hardy-Bessard, Anne-Claire, additional, Chaix, Marie, additional, Kim, Byoung-Gie, additional, Kim, JaeWeon, additional, Park, JeongYeol, additional, Lee, Jung-Yun, additional, Lim, MyongCheol, additional, Kim, Kidong, additional, Cho, Hyun-Woong, additional, and Joly, Florence, additional

Published
2024
Full Text
View/download PDF

47. Durvalumab (Durva) plus carboplatin/paclitaxel (CP) followed by durva±olaparib (Ola) as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial

Author

Westin, Shannon N, primary, Moore, Kathleen N, additional, Chon, Hye Sook, additional, Lee, Jung-Yun, additional, Pepin, Jessica Thomes, additional, Sundborg, Michael, additional, Garza, Joseph de la, additional, Nishio, Shin, additional, Wang, Ke, additional, McIntyre, Kristi, additional, Tillmanns, Todd D, additional, Mejia, Fernando Contreras, additional, Melo, Andreia Cristina De, additional, Klasa-Mazurkiewicz, Dagmara, additional, Papadimitriou, Christos, additional, Gil-Martin, Marta, additional, Brasiuniene, Birute, additional, Donnelly, Conor, additional, Liu, Xiaochun, additional, and Nieuwenhuysen, Els Van, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results